Soligenix, Inc. — Q1 2016 Form 10-Q
Period: Three months ended March 31, 2016; unaudited. Soligenix is a late-stage biopharmaceutical company developing rare-disease therapies across BioTherapeutics and Vaccines/BioDefense. Revenue is principally from government contracts and grants, not product sales.
Key financial metrics
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Revenue | $2.631 million | $0.816 million |
| Gross profit and margin | $0.399 million; 15.2% | $0.289 million; 35.4% |
| Operating expenses | $2.304 million | $1.847 million |
| Operating loss | $(1.906) million | $(1.558) million |
| Net loss | $(1.149) million | $(4.569) million |
| Net loss per share | Basic $(0.04); diluted $(0.06) | Basic and diluted $(0.19) |
| Operating cash flow | $(0.638) million | $(1.506) million |
| Cash and cash equivalents | $4.260 million | $4.922 million at Dec. 31, 2015 |
| Working capital, excluding warrant liability | $0.406 million | $2.180 million at Dec. 31, 2015 |
| Current liabilities / warrant liability | $6.641 million / $1.674 million | $7.405 million / $2.434 million at Dec. 31, 2015 |
Notes payable were $299,000 at quarter-end; the company reports repayment on April 15, 2016. Accounts payable were $4.633 million. Total assets were $5.591 million and shareholders’ deficiency was $1.050 million. The company had 31,369,522 common shares outstanding at March 31 and reported 31,472,522 as of May 6, 2016.
Changes versus the prior comparable period
- Revenue increased 222%, primarily from higher activity under BARDA and NIAID contracts supporting OrbeShield and RiVax. These contract revenues are reimbursement-based.
- Gross profit increased 38% in dollars, but margin fell from 35.4% to 15.2%; management attributed the decline to reimbursable costs that did not qualify for fixed overhead reimbursement.
- Research and development expense rose 39% to $1.428 million, primarily due to the SGX301 pivotal Phase 3 trial. General and administrative expense increased 7% to $0.876 million.
- Operating loss widened by $0.347 million. Reported net loss improved by $3.420 million chiefly because the warrant liability generated $0.760 million of noncash income in 2016, versus a $3.012 million noncash charge in 2015.
- Cash used in operations declined to $0.638 million from $1.506 million; cash nevertheless fell $0.661 million during the quarter. Working capital, excluding the noncash warrant liability, declined 81% from year-end.
Outlook, developments and risks
- Management said available cash, expected government contract and grant proceeds, equity facilities and potential New Jersey NOL-sale proceeds should fund working capital and capital expenditures for at least 12 months. This depends on anticipated funding and financing sources being available; the filing does not assure their realization.
- The company estimated approximately $11.2 million of R&D spending over the next 12 months before reimbursements ($4.5 million BioTherapeutics and $6.7 million Vaccines/BioDefense), with approximately $6.7 million of anticipated contract and grant revenue to offset Vaccines/BioDefense R&D. It reported up to $40.3 million of active government funding available for associated programs.
- Pipeline milestones included expected SGX301 Phase 3 data in the second half of 2016; a planned SGX203 Phase 3 study in the second half of 2016; and continued SGX942 long-term follow-up, with final Phase 2 results expected in Q4 2016 and FDA protocol discussions planned for the second half of 2016. These are forward-looking expectations, not assured outcomes.
- In the SGX942 Phase 2 study, the company reported a 50% reduction in median duration of severe oral mucositis at the 1.5 mg/kg dose across all patients (18 to 9 days; p=0.099), and a 67% reduction among patients receiving the most aggressive chemoradiation (30 to 10 days; p=0.040). Preliminary results require consideration alongside the ongoing follow-up and subsequent study evidence.
- Liquidity options include a Lincoln Park facility allowing up to $12 million of purchases over approximately 36 months, subject to agreement terms and market conditions, and potential further equity issuance. The filing also cites $8.2 million available from facilities expiring in November 2016; separately, it says the July 2015 equity purchase agreements were terminated in March 2016. Clarification of the cited facility availability is warranted.
- Contractual obligations shown for 2016–2020 total $771,000. Separate agreements may require up to $7.9 million in milestone payments and royalties up to 6% of covered net sales; the Hy Biopharma agreement also provides for up to $10 million in success-based payments. No such milestone or royalty amounts had been paid or accrued at quarter-end.
- Key risks include dependence on government funding and external financing, clinical and regulatory uncertainty, and potential dilution. The $760,157 warrant fair-value gain is noncash and valuation-dependent. Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Availability, draw conditions, expiry dates and potential dilution from the equity facilities, particularly the stated $8.2 million facility in light of the reported March 2016 termination.
- Actual cash runway and government reimbursements against the planned R&D spend, given the 81% decline in working capital excluding warrant liability.
- Enrollment, timing and results of the SGX301 Phase 3 trial, and final SGX942 Phase 2 follow-up and regulatory plans.
- How much of reported revenue and gross profit reflects reimbursed contract activity, and whether the lower gross margin persists.
- Potential effects of warrant remeasurement, future equity issuance, and contingent milestone or royalty obligations on reported results and shareholders.